Navigation Links
REACH news: European ombudsman takes up PETA complaint
Date:1/30/2013

London In response to a complaint by People for the Ethical Treatment of Animals (PETA), the European Ombudsman has launched an inquiry into the actions of the European Union (EU) agency responsible for the administration of the REACH chemical-testing program, which is expected to consume millions of animals in toxicity tests. PETA's complaint, submitted in July 2012, alleges that the European Chemicals Agency (ECHA) is not properly investigating cases in which animal testing could be avoided under the rules of REACH. PETA maintains that evidence derived from public documents and correspondence with the agency demonstrates that ECHA is not taking the necessary steps to ensure fulfilment of REACH's legal requirement that animal testing be conducted only as a "last resort."

The REACH Regulation (1907/2006/EU) makes clear in recitals, articles and annexes that animal tests must be avoided whenever possible, but in 2011 the agency's report "The Use of Alternatives to Testing on Animals for the REACH Regulation" showed that tens of thousands of animals were used in tests that could have been avoided under REACH's own rules. These tests included 135 skin-irritation studies conducted after a non-animal replacement had been validated and approved for use under REACH and 107 studies conducted without prior submission and approval of a testing proposal.

In response to the report, PETA contacted ECHA and the European Commission to seek assurances that all such possible violations of the requirements were being investigated by the agency and/or reported to relevant national authorities. PETA's enquiries have revealed that ECHA is not taking action to investigate all the 107 tests on animals conducted without test proposals, does not directly inform member state authorities of all possible violations of last-resort requirements and does not assess information dossiers submitted by chemical companies to evaluate whether animal tests undertaken for REACH could have been avoided.

In its complaint, PETA argued that in failing to properly evaluate whether animal tests had been conducted as a last resort in accordance with REACH's requirements, ECHA was guilty of maladministration. It is this complaint which the Ombudsman took up in December.

"PETA alleges that animals may have been poisoned and killed in tests that should never have taken place," says PETA UK Science Adviser Dr Gilly Stoddart. "We are relieved that the Ombudsman has launched an inquiry, as the lives of millions of animals are at stake. We trust that the Ombudsman will share our view and compel the agency to fulfil its obligations."


'/>"/>

Contact: Tasgola Bruner
TasgolaB@peta.org
770-518-1675
People for the Ethical Treatment of Animals
Source:Eurekalert

Related biology news :

1. ImpactStory metrics of academic research outreach piloted by Pensoft Publishers
2. A call to prevent unsafe high-risk medical devices from reaching the marketplace
3. Nanoparticles reach new peaks
4. GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury
5. $1 million Kenan Trust Grant extends support of Scripps Florida education outreach
6. Crank Software Selects TREW Marketing for Embedded Industry Outreach
7. Global Market for Nanotechnology to Reach $3.3 Trillion by 2018
8. New public gut bacteria study expected to reach around world
9. Airborne particles smuggle pollutants to far reaches of globe
10. Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn
11. Sea surface temperatures reach record highs on Northeast continental shelf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
Breaking Biology Technology: